When your OR is selecting allograft tissue, how do you know which federal regulations govern their safety? The US Food and Drug Administration (FDA) uses a tiered approach to regulating these materials, explains Scott Brubaker, CTBS, chief policy officer for the American Association of Tissue Banks (AATB). Minimally processed tissue…
Screening of tissue donors is a critical step in ensuring tissue safety. Screening is a complex, multidisciplinary process that begins every time a family says "yes" to the option of donation and ends when tissue is released for transplant. Tissue banks vary in what is considered a suitable donor. Regulating…
These are examples of types of bone allograft products and purposes they serve. With the chart on page 12, this information can help OR teams determine where a new allograft product would fit into current inventory. Allograft cancellous chips Cancellous chips, a common nonstructural human allograft bone material, serve as…
A surgeon has requested a new tissue graft not in the current inventory. From the company's literature, it's not easy to tell whether the tissue is similar to others already in stock. Decisions like these are challenging because tissue grafts come with a host of safety, clinical, and cost issues.…
A special article on new Joint Commission expectations. By January 2012, the Joint Commission plans to raise the bar on hospital performance by using ORYX core measure data more directly in the survey process. In the 8 years since the Joint Commission launched ORYX, its performance measurement and improvement initiative,…
OR business managers and others involved in the financial management of perioperative services will find a track specifically for them at the Managing Today's OR Suite Conference September 28-30, 2011, in Chicago. The OR Business Management Conference is being combined with Managing Today's OR Suite this year. The track features…
The few ambulatory surgery centers (ASC) that use full electronic medical records (EMR) systems are not only ahead of their colleagues in the ASC industry. They are outpacing most hospitals as well. That does not mean others can safely ignore the trend. Before long, industry experts agree, health care organizations…
Fifth and final article in a series on managing bone allografts. A unified program for managing biologics, including tissues and blood, has helped a Massachusetts hospital to meet regulatory requirements, track adverse events, and have a consistent process for bringing new tissues into the organization. The 2½-year-old Biovigilance Program at…